US 8,026,049 B2 · Noninvasive measurement and identification of biomarkers in disease state

Abstract

The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.

Claims9

Dependent claims

A method for providing information useful for diagnosing a disease state in a subject comprising:

a) obtaining a biological sample comprising a plurality of biomarkers from the subject, wherein the biomarker levels are related to the disease state, and the disease state is sepsis;
b) detecting the plurality of biomarkers;
c) determining a profile of the detected biomarkers;
and
d) comparing the profile of the detected biomarkers to a standard biomarker profile, wherein the profile of the detected biomarkers comprise Ala, Tyr and His each having increased levels of at least 50% compared to the standard biomarker profile, thereby providing information useful for diagnosing sepsis.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/054,153Filed 24 Mar 2008 · us provisional application

Priority

23 Mar 2007

Published

US 2009/0104596 A123 Apr 2009

Granted

27 Sep 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

G01N 33/6893
Involving proteins, peptides or amino acids: related to diseases not provided for elsewhere
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/158
Oligonucleotides characterized by their use: expression markers
G01N 2800/26
Detection or diagnosis of diseases: infectious diseases, e.g. generalised sepsis

Noninvasive measurement and identification of biomarkers in disease state

Life of this patent

Noninvasive measurement and identification of biomarkers in disease state

Life of this patent

Abstract

Claims9